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Bioinformatics is the use of computers for the storage, recall and analysis of data
derived from scientific research aimed at providing answers to biological questions.
Increasingly pharmaceutical firms are choosing to incorporate bioinformatics into
their drug research and development (R&D) programs.
Based on examination of recent literature and case studies of a cross section of the
pharmaceutical industry and research community, this research concludes the
following key points:
·  Bioinformatics has been widely accepted as a new core competency for
pharmaceutical research.
·  Pharmaceutical firms are broadening their competencies to different extents to
access new technologies.
·  Integrated bioinformatics systems are systemic innovations and require strong in-
house capabilities, however bioinformatics tools may also be used in an
autonomous manner.  Thus two groups of industrial users are emerging: those
who use bioinformatics tools piecemeal and those who are attempting to integrate
these tools into systems.
·  Integration poses a complex set of technical and organisational problems, but may
enable high throughput programs for drug discovery that optimise resources more
effectively and thus provide competitive advantages.
·  Such integrated systems must be tailor-made and are possible only through
gaining competencies that are difficult to replicate.
Additionally in this study theoretical frameworks are used to map technological
change in the pharmaceutical process, showing how barriers to innovation and
limiting steps within the R&D process are changing as a result of bioinformatics.Chapter 1: Introduction
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Chapter 1: Introduction
1.1 Purpose
The early 1990’s saw the establishment of bioinformatics departments in the largest
firms of the pharmaceutical industry.  This move was prompted primarily by the need
to store and analysis large amounts of DNA sequence data that had become available
through the activities of academics and small specialised genomics
1 firms such as
Human Genome Sciences (HGS) and Incyte Pharmaceuticals in the United States.
Bioinformatics is the:
“storage, retrieval and analysis of data for scientific research aimed at providing
answers to biological questions.”
This definition encompasses computerised tools and techniques used for the study of
sequences and structures relating to DNA, proteins and other molecules in biological
systems.  The term Computational Biology may also be used by some sources to
describe this field.  At present the most commonly used of these in pharmaceutical
research are of the following types:
Software tools
2 exist to create and compare 3-D structural models of proteins and
other molecules, to aid prediction of their interactions.    Models may be drawn from
local or remote databases.  Additionally, tools also exist to find and compare DNA
and protein sequences drawn from local and remote databases.  Both these groups of
tools are generally run on workstations with intra/ internet links. These computers
have more powerful processing and graphics abilities than standard PCs, but are less
powerful and expensive than mainframe computers.
It was hoped the ability to read DNA sequences would allow deeper understanding of
the susceptibility of individuals to disease, as well as giving greater insight into the
                                                          
1 See glossary for definition2
structure and assembly of proteins.  Knowledge of protein structure would enhance
the ability of pharmaceutical firms to find or design molecules to “dock” with these
proteins and thus alter their performance producing a therapeutic effect.   Thus
bioinformatics was needed as a set of enabling tools to store and interpret the newly
available data.
Given the growing importance of bioinformatics to the pharmaceutical industry, the
key questions addressed in this project are:
·  How has bioinformatics been integrated into the drug research and
development processes of the firm?
·  What strategies have pharmaceutical firms used to acquire capabilities in
bioinformatics?
1.2 Argument
The argument presented here is bioinformatics constitutes a new core competency for
pharmaceutical firms.  In an industry with increasing regulatory requirements, rising
R&D costs and increasing competition for market share, bioinformatics offers the
means of acquiring a greater insight into the causes of disease and the structure and
mechanisms of lead compounds
3 for therapeutic agents.  Increasing such knowledge
guides strategic decisions, and thus may reduce the likelihood of poor drug
candidates
4 entering the clinical trials process and resulting in expensive failures.
Additionally by automating many stages of research, higher throughput of lead
candidates may be achieved, thus enhancing firm’s development pipelines.
Therefore firms optimising bioinformatics systems within their R&D process will
                                                                                                                                                                     
2 See glossary for definition
3 See glossary for definition
4 See glossary for definition3
derive a competitive advantage
5 over firms failing to effectively utilise the new tools.
Firms’ strategies for accessing bioinformatics are varied, as are their internal
organisational capabilities, and this may result in a new source of competitive
advantage in the industry.  The extent to which firms can develop bioinformatics is
dependent on available resources. Organisational and technological problems arise
due to the complexity of integrating software systems and these are expensive and
time consuming to solve.  Only the largest firms with great investments of time and
resources can achieve fully integrated bioinformatics systems and derive maximum
competitive advantage.  Whilst smaller organisations can access basic bioinformatics
tools at relatively low cost, they cannot afford the numbers of staff and other
resources necessary to integrate these tools into a tailor-made system allowing
optimum results.
1.3 Frameworks Adopted
Two bodies of literature are used in pursuing the argument above: literature
describing pharmaceutical R&D processes specifically, and literature debating the
management of technological innovation within corporate strategy.
In mapping technological change in the drug R&D process it is necessary to examine




These frameworks show that the classical drug R&D process has been changed
dramatically, with new stages replacing old, and a broader choice of techniques
                                                          
5 A relative advantage over competitors in that lowering overall costs of failed products allows more
resources to be spent on developing greater numbers of viable drug candidates before competing firms
can gain market share in the therapeutic market for a given condition.
6 Nightingale, P (1997) Knowledge and Technical Change: Computer Simulations and the changing
Innovation Process, Sussex University
7 Lyall, A, (1996) Bioinformatics in the Pharmaceutical Industry, Trends In Biotechnology, vol.14
p.308-312 & Lyall, A, (1998) “Informatics – The Key to redesigning Drug Discovery” European
Biopharmaceutical Review, March.
8 Jean, T, (1997) Drug Discovery CROs,  European Pharmaceutical Review, September, p.36-414
available for use.  Limiting factors that determine time and cost of drug discovery are
also revealed.
In the management of technological innovation literature, it is suggested the nature of
technological change in the pharmaceutical industry has consisted of dramatic
paradigm shifts, as defined by Dosi
9&10, where by the heuristics of R&D have been
changed, first by biotechnology
11 and more recently by bioinformatics
12. In theories
of technological innovation authors have asserted firms faced with change are
constrained in their choice of action by their technological trajectory
13.  To adapt to
changing technological circumstances, firms must access new capabilities.  The
question of whether to develop these capabilities in-house or to access them through
external linkages may be answered by considering their application
 and whether it
relates to autonomous or systemic innovation
14 as suggested by Chesbourgh &
Teece
15.  This concept is important for firms considering how best to access and use
bioinformatics capabilities. Granstrand, Patel & Pavitt
16 demonstrate that large multi-
technology firms have a broad spectrum of technological competencies, wider than
indicated by examining their product range.  Firms must maintain this position in
order to explore new technological options available to them, as well as to manage
                                                          
9 Dosi, G (1982) Technological Paradigms and Technological Trajectories: A Suggested Interpretation
of the Determinants and Directions of Technological change, Research Policy, Vol. 11 No.3 p.147-62
10 Dosi, G (1988) The Nature of Innovative Process, Chapter 10, in Dosi, G, Freeman, C, Nelson R,
Silverberg, G, and Soete, L, Technical Change and economic Theory, Frances Pinter, London
11 Sharp, M (1989) Collaboration and The Pharmaceutical Industry Is It The Way  Forward, SPRU,
Sussex university
12 Lander, E, Langridge, R, Saccocio, D (1991) Mapping and Integrating Biological Information,
Communications of the ACM Vo1. 34, No.11
13 Nelson, R & Winter, S (1977) In search of a useful theory of Innovation, Research Policy, vol. 5,
p.36-76
14 The benefit from Autonomous innovations can be realised independently of other systems, for
example a turbocharger can be introduced to car without having to design the engine.  However
systemic innovations require changes in supporting systems, for example Polaroid technology required
not only a new film, but a new camera too (Chesbourgh & Teece, 1996).
15 Chesbourgh, H, & Teece, D (1996) When is Virtual Virtuous? Harvard Business Review, January –
February, p.65-74
16 Granstrand O, Patel P, Pavitt K (1997) Multi-Technology Corporations: Why They Have Distributed
Rather Than Distinctive Core Competencies, California Management Review Vol.39 No.4 p.8-255
and co-ordinate technical change. Thus Granstrand Patel & Pavitt imply firms should
develop bioinformatics capabilities in-house to fully manage and benefit from
technological changes in bioinformatics and, because it is an enabling technology,
other related fields.    Teece and Pisano
17 argue the co-ordination of technological
change and the ability to gain competitive advantage from it is derived from firms’
dynamic capabilities.  Like Granstrand Patel & Pavitt, Teece and Pisano also
emphasise it is not just capabilities that are important, but the ability to change and
adapt capabilities as well. They emphasise the importance of firms’ paths, positions
and processes in contributing to the formation of dynamic capabilities and the
importance of apropriability regimes in determining whether or not a firm will be
successful in creating competitive advantage from new capabilities such as
bioinformatics.
The frameworks presented by Chesbrough and Teece (1996) ,Granstrand, Patel, and
Pavitt (1997), and Teece and Pisano (1994) are further considered in explaining the
significance of this study’s findings.
1.4   An Introduction to Biotechnology – A New paradigm for Pharmaceutical
        Development
Biotechnology is a broad term for a group of enabling technologies that allows “the
application of scientific and engineering principles to the processing of material by
biological agents”




  (or “modern” biotechnology) has its
                                                          
17 Teece D, Pisano, G (1994) “The Dynamic Capabilities of Firms”, Industrial & Corporate Change,
Vol.3 No. 3, p537-556.
18 OECD (1992) Biotechnology: International Trends and Perspectives
19 Sharp, M (1990) Pharmaceuticals and Biotechnology: Perspectives for the European Industry, SPRU
Sussex University:6
genesis three years after the first software computer.  In 1952, Watson and Crick
determined the structure of Deoxyribose Nucleic Acid (DNA), the molecule that acts
as a blueprint for virtually all organisms. In 1973, Cohen and Boyer published an
account of the first successful recombination or splicing of DNA from two species.
For the first time characteristics could be transferred between unrelated species, and
existing characteristics could be altered.   Cohen and Boyer went on to form
Genentech in the US, the first modern “biotech firm”.  The ability to sequence DNA,
and “read” the instructions to make the building blocks of life came from the work of
Fredrick Sanger at Cambridge University in 1975.  His technique proved it possible to
predict certain characteristics of individuals from studying their DNA.  Over recent
years, DNA sequencing
20 has become more efficient and less expensive, leading to
the routine sequencing of genes and even entire genomes in laboratories across the
world.  The establishment of the Human Genome Project (supported by the US
government and the Wellcome Trust) has brought hopes that all 3 billion bases and
100,000 genes of human DNA will be available to the public sector by 2005.
Meanwhile Human Geneome Sciences (HGS) and Perkin Elmer working in a joint
venture hope to complete their own similar program some years earlier to provide
novel targets
21 for pharmaceutical research
22.  Research into the genomes of numerous
other species is being undertaken.  These include animals such as the mouse, and
Drosphilla (fruit fly), plants including Arabidopsis, rice, wheat, and soya, micro-
                                                                                                                                                                     
1
st generation: The use of bacteriological fermentation in processes for producing goods such as wine
and cheese; cross breeding of plants and animals to produce offspring with favoured characteristics.
2
nd generation: The microbiological “revolution” of the late 19
th and early 20
th centuries brought
advances in fermentation techniques, the first vaccines and antibiotic treatments.  Additionally
enzymes and applied microbiology because increasingly used.
3
rd generation: The discovery of DNA and Genetic engineering, allows transfer of characteristics
between species by use of various vectors, and the design of drugs, proteins and therapeutic tools.
20 See glossary for definition
21 See glossary for definition
22 Knight, J & Kleiner, K, Genome Project Goes Into Overdrive, New Scientist, No.2134 16
th May
19987
organisms such as yeast (the first completed eukaryotic genome), E.coli, as well as a
host of extremeophiles (bacteria with remarkable adaptations to difficult living
environments such as volcanic springs or deep ocean trenches).  The research from
such projects provides novel techniques and products not just for the pharmaceutical
industry, but the healthcare, agriculture, environmental management, mining,
chemical industries too, and it may well find applications in other areas.
1.5 The Changing face of the Pharmaceutical Industry
Over recent years the sources of innovation for the pharmaceutical industry have
changed dramatically from the traditional pharmacological techniques which sufficed
for several decades
23.  New developments resulting from modern biotechnology
(referred to from now on as simply biotechnology) offered revolutionary
technological change, indeed some speculators saw biotechnology as a Schumpeterian
competence destroying advance which would bring down the incumbent
pharmaceutical firms
24.  Entrepreneurs sparked an explosion in new Dedicated
Biotechnology Firms
25 (DBFs) which started in the US and spread globally.  There
are around 1300 such firms in the US and 1000 in Europe
26.  DBFs faced numerous
problems both in becoming integrated pharmaceutical firms and in producing
marketable products.  They lacked down stream capabilities such as production, sales
and distribution, had no experience of running clinical trials, and more fundamentally
many of the DNA or protein based therapies they developed had inadequate delivery
mechanisms to ensure they reached the cause of the patient’s illness.  As a result a
                                                          
23 Galambos, L & Sturchio, J (1997) Science in the Twentieth Century, Chapter 13
24 Kenney, M, (1986) “Schumpeterian Innovation and entrepreneurs in Capitalism: A Case Study of the
U.S. Biotechnology Industry” Research policy 15, p.21-31.
25 See glossary for definition
26 Ernst & Young (1998) European Life Sciences 98 - Continental Shift8
mere 40 or so therapeutic compounds derived from biotechnology have been FDA
27
licensed, and only a handful of profitable DBFs exist
28. Faced with high barriers to
entry into the pharmaceutical industry as fully integrated firms, DBFs are increasingly
contenting themselves in becoming “drug discovery” firms, or Contract Research
Organisations
29 (CRO) undertaking niche activities for other firms
30.  Thus it appears
biotechnology has not proved competence destroying and the incumbent
pharmaceutical firms’ competitive advantage has so far been maintained
31.
Until the development of biotechnology, pharmaceutical firms had generally
concentrated their research in-house. However, many of the techniques that
biotechnology made possible were attractive to pharmaceutical firms, but only
available from DBFs and universities.  Pharmaceutical firms found these new
techniques attractive because traditional methods of drug discovery were producing
diminishing rates of return.  These techniques, used since the “golden age” of
pharmaceuticals in the 1950’s and 1960’s, had uncovered the obvious drug
candidates, and finding new therapeutics was becoming increasingly expensive and
time consuming
32.  To gain access to the new technologies offered by biotechnology,
firms had to form alliances either with DBF’s or universities with these capabilities.
Indeed one reason for the growth of DBF’s is seen as entrepreneurial academics
facilitating the requirements of large firms
33.  The initial skill shortage was such that
large firms might have had difficulty in establishing internal departments in these
                                                          
27 See glossary for definition
28 Aharonian, G, Patent News, 21 August 1997 (available from srctran@world.std.com)
29 See glossary for definition
30 Rau, N (1997) Biopharmaceuticals in Europe - A Rich ground for Partnering, European
Biopharmaceutical Review, September. p.20-29
31 Pisano, P (1990) “The R&D Boundaries of The Firm: An Emperical Analysis”, Administrative
Science Quarterly, 35 p. 153-176
32 Sharp, M (1989) Collaboration and The Pharmaceutical Industry Is It The Way  Forward, SPRU,
Sussex University, p.8.
33 Sharp, M (1989) Collaboration and The Pharmaceutical Industry Is It The Way  Forward, SPRU,
Sussex University, p.17.9
areas, and this was one reason behind the growth of an alliance culture.  However, the
large firms also benefited from alliance formation with DBF’s because they could
maintain a window of opportunity on biotechnology developments without the
expense of investing too heavily to bring risky projects in-house.  In return for
investment large firms would receive licensing rights and could share knowledge
created within the alliance.  Only later when new trajectories in the development of
biotechnology became clearer did firms choose to develop internal capabilities.
Figure 1.1 below shows the growth of alliances between European pharmaceutical
firms and DBFs in the 1990’s.
Source: p.12, Thomas S, Birtwistle N, Hopkins M & Simmonds N,  (1998) The Impact of Intellectual
Property on The Development of European Biotechnology, SPRU, Sussex University.












Figure 1.1 The Growth of Alliances Between
European Pharmaceutical Firms and DBFs10
As Sharp predicted
34 alliance formation has occurred mainly between large
pharmaceutical firms and DBFs.  There is an absence of significant numbers of
alliances between two large firms (other than mergers)
35 as may be seen in other
industries such as consumer electronics (e.g. Sony and Philips in the case of CD
development).  However, large firms have been involved in significant consolidation
activity, which has contributed towards an increased concentration in market share in
an industry that has been historically relatively un-concentrated.  As the data in figures
1.2, 1.3, and 1.4 below show, the concentration of market share held by the top ten
pharmaceutical firms has increased by over 20% in the past nine years.  Furthermore,
the top ten firms in 1995/6  consists of 13 top 25 firms from 1989.  More appetite for
consolidation was shown by American Home Products, Glaxo-Wellcome, and
Smithkline Beecham in abortive merger talks earlier this year.  Although the trend of
consolidation is slow relative to other industries (such as Aerospace or Electronics)
over recent years, it is important to note increasing financial pressures on some of the
world’s largest firms.
                                                          
34 Sharp, M (1989) Collaboration and The Pharmaceutical Industry Is It The Way  Forward, SPRU,
Sussex university, p.27
35 Thomas, Birtwistle, Hopkins & Simmonds,  (1998) The Impact of Intellectual Property on The
Development of European Biotechnology, SPRU, Sussex University.11
Figure 1.2: Top Ten Pharmaceutical Firms in 1987 (by Global Market Share)
Position Pharmaceutical Firm Market
Share (%)
1 Merck  3.8
2 Hoecht  3.2
3G l a x o  3 . 1
4 CibaGeigy  2.9
5 Bayer  2.7
6 American Home Products  2.6
7T a k e d a  2 . 5
8 Sandoz  2.5
9  Eli Lilly  2.2
10 Abbott  2.1
Total
27.6 %
Source: p.7 Sharp, M (1989) Collaboration and the Pharmaceutical Industry- Is It The Way Forward?
SPRU, Sussex University
Figure 1.3: Top Ten Pharmaceutical Firms in 1989 (by Global Market Share)
Position Pharmaceutical Firm Market
Share (%)
1 Merck  4.5
2 Bristol Squibb  3.5
3G l a x o  3 . 5
4 Hoechst  3.3
5 SmithKline Beecham  3.0
6 Bayer  2.8
7 American Home Products  2.6
8 Ciba Geigy  2.5
9  Eli Lilly  2.4
10 Sandoz  2.3
Total
30.4 %
Source: adapted from p.3 Sharp(1990) Pharmaceuticals and Biotechnology: Perspectives for the
European Industry, SPRU, Sussex University
Figure 1.4: Top Ten Pharmaceutical Firms in 1995/96 (by Global Market Share)
Position Pharmaceutical Firm Market
Share (%)
1 Glaxo Wellcome 4.7
2 Novartis (Sandoz + Ciba Geigy) 4.5
3 Merck 3.5
4 Hoechst/ MMD 3.5
5 Bristol Myers Squibb 3.1
6 American Home Products 3.0
7 Pfizer 2.9
8 Johnson & Johnson 2.9
9 Roche 2.6
10 SmithKline Beecham 2.5
Total
33.2 %
Source: p.9 Sharp, Patel & Pavitt (1996) Europe’s Pharmaceutical Industry: An Innovation Profile
SPRU, Sussex University12
One of the factors driving this trend towards consolidation is the increasing cost of
R&D.  Although estimates of the true cost of bringing a drug to market are not always
clear,
36 estimates vary between $100-400 million dollars per drug, and even more if
the cost of paying for failed projects is factored into the R&D cost of successful
products (See figure 1.5 below).
Figure 1.5 The Rising R&D Cost of Bringing A New Drug To Market
Source: p.1318, Drews & Ryser (1997) The role of Innovation in Drug Development, Nature
Biotechnology Vol.15 No.13
This trend is likely to continue, given FDA plans to make drug licensing more
stringent
37.
                                                          
36 Love, J, Call for More Reliable Costs Data on Clinical Trials, Marketletter, January 13
th 1997, p.24
(also available at http://www.cptech.org/pharm/marketletter.html)


















Further financial pressure is placed on pharmaceutical firms through the cost cutting
activities of healthcare organisations globally.   These organisations seek to cut
pharmaceutical expenditure as they become more stretched by aging populations and
funding shortages.  One cost saving strategy is to purchase cheaper generic copies of
novel drugs, once these become available as patents expire.
Although consolidation in the industry may save a degree of expense, and combining
product portfolios ensures protected revenue streams, this is horizontal integration,
and large firms still require vertical integration to access new research techniques
generated by biotechnology
38.  Acquisitions of DBFs by large pharmaceutical firms
have occurred (for example Hoffman La Roche and Genentech in 1990, Rhone
Poulenc Rorer and Applied Immune Sciences in 1993, Ciba-Geigy and Chiron in
1994, Glaxo and Affymax in 1995 all for sums between $100million and $2000
million
39).  However, alliance formation provides cheaper access to research, and so
pharmaceutical firms are able to form portfolios of alliances.       
This strategy for gaining access to new technologies is now widespread.  Gambardella
notes:
“In view of increasing complexity and multi-disciplinarity of knowledge, external
information is critical to the development of innovations.  What is nowadays more and
more important is not the production of information but the dynamics and
transformation of a larger pool of information.  Information exchange, rather than
retaining it within one’s own organisational boundaries, is a major determinant of
successful innovation.  But this requires that one is prepared to diffuse research
findings in exchange for the knowledge produced by others: To be part of a network,
and to be able to effectively exploit the information that circulates in the network, has
                                                          
38 Sharp, M (1989) Collaboration and the Pharmaceutical Industry – Is It The Way Forward? SPRU,
Sussex University.14
become even more valuable than being able to generate new knowledge
autonomously.”
Source: p.32 Gambardella, A (1991) Competitive Advantages From In-House Scientific Research:  The
US  Pharmaceutical Industry in the 1990’s, IEFE, Universities of Bocconi
Additionally, competitive advantage may also be derived from the ability to follow
external events and select the right alliance partners to benefit from technological
advances, given there may be many potential DBF partners seeking alliance with any
one large pharmaceutical firm.  This is an ability firms might not be able to optimise
without maintaining internal competencies in the field
40.
The rise of information intensive technologies such as genomics, proteomics
41,
structural modeling and combinatorial chemistry
42, cause alliances to increasingly
center on the exchange of vast quantities of data.  These data are often difficult or
even impossible to interpret without computer programs.  Thus to effectively utilize
data across large (sometimes global) R&D departments requires a complex computer
infrastructure.  Within this infrastructure, bioinformatics facilitates the use of new
technologies that would otherwise overwhelm researchers with raw information.  Like
biotechnology before it, bioinformatics has been termed a paradigm shift
43.  It
changes the fundamental way in which drug discovery is undertaken in almost every
stage of the process, and without it the use of a host of other technologies cannot be
optimised.  Indeed as Gelbert and Gregg of Bristol Myers Squibb noted:
“No one technology has been or is anticipated to be, the major driving force behind
the revolution in the discovery and development of new drugs.......The major scientific
                                                                                                                                                                     
39 as listed on the biotech alliance database available at www.RECAP.COM.
40 Granstrand O, Patel P, Pavitt K (1997) Multi-Technology Corporations: Why They Have Distributed
Rather Than Distinctive Core Competencies, California Management Review Vol.39 No.4 p.8-25
41 See glossary for definition
42 See glossary for definition
43 Lander, E, Langridge, R, Saccocio, D (1991) Mapping and Intergrating Biological Information,
Communications of the ACM Vo1. 34, No.1115
disciplines and technologies that are revolutionizing drug discovery are advances in
cellular and molecular biology, the advent of combinatorial chemistry, the
development of high-throughput screening
44, high resolution structural biology and
data acquisition and processing systems to handle the ever increasing stream of
information from biology, screening and chemistry.”
Source: p.669 Gelbert, L, and Gregg, R, (1997) Will genetics really revolutionize the drug discovery
process? Current Opinion in Biotechnology, Vol.8
The benefit of these new technologies to pharmaceutical and drug discovery firms
relies on developing a capability in bioinformatics.  Again, as with the development
of biotechnology, there is a shortage of trained bioinformaticians (those who can
create, integrate and use specialist software tools).    The demands firms place on
their bioinformatics infrastructures are also complex, as the rate of progress in these
fields is very rapid
45.  The nature of research questions posed changes quickly, and so
the nature of data generated also changes quickly.  This results in successive waves of
data that must be fed into the systems databases for analysis as Lyall demonstrates in
figure 1.6.
    Shown as several successive waves of data, new fields of interest may
hold a focus of attention for a short period, rapidly generating large data sets.
However the next fields focused on may generate very different types of data, which
must be related to the previous set.  For example to find the genes responsible for
controlling a metabolic pathway, it might be necessary to draw on data from mapping,
ESTs, and genomic data sets, but mapping information will be positional, where as
                                                          
44 See glossary for definition
45 Gelbert, L, and Gregg, R, (1997) Will genetics really revolutionize the drug discovery process?
Current Opinion in Biotechnolgy, Vol.8 p.669-67416
genomic information will be related to gene sequence.  The information can be related
in complex databases, but failure to do so results in creation of islands of data.





    Source:  p.57  Lyall, A, “Informatics – The Key to redesigning Drug Discovery” European
Biopharmaceutical Review, March 1998.
Additionally challenges such as integrating new tools with each other and with
existing processes, as well as training staff must all be taken into account.  Although
he does not mention bioinformatics or genomics in his book on process innovation in
the pharmaceutical industry, Pisano notes there is little discussion in current strategy
literature of how a strong process development capability in the pharmaceutical
industry may strengthen a firm’s competitive ability
46.  Certainly such abilities would
be important in solving the problems bioinformatics poses:
·  The need to restructure existing routines to incorporate new techniques.
·  Complex nature of data produced and their interpretation.
·  Rapid pace of change, requiring new software tools and robust data storage
methodologies.
                                                          
46 Pisano, G (1997) The Development Factory, Harvard Business School Press, p.3
Mapping ESTs Genomic Pathways Expression17
·  Complexity of integrating software tools together to form suites of tools and
databases.
·  Cultural problems surrounding re-training of old staff and recruitment of new
staff.
  Firms that fail to demonstrate an ability to manage these changes may find the
integration of bioinformatics difficult, and thus will not realize the full potential of the
new technologies associated with it.  Given the increasingly competitive environment
they inhabit, this may prove to be a very important factor in determining their future
success.
1.6 Methodology
To answer the questions posed in section 1.1, data were gathered from both primary
and secondary sources.  The primary sources for interview were nine organisations
involved with bioinformatics who provided a total of 12 interviewees (Appendix 1).
Secondary data from numerous publications and web sites were also used.
1.6.1 Interviews and Their Limitations:
Given the finance and time constraints of this project only a small number of UK
based interviewees were selected.  Due to these limitations, interviews were arranged
with a representative cross section of the bioinformatics user community in order to
establish current opinions in the field.
Five firms were interviewed. These included three large fully integrated
pharmaceutical firms referred to as A, B and C one medium sized fully integrated
pharmaceutical firm, D, and a small DBF specializing in drug discovery, E.
Additionally a representative from one small firm, F, specializing in bioinformatics18
development and consultancy was interviewed.  Given the importance of public
research organizations in the growth of bioinformatics, the cross section also included
two representatives of the academic research community which were the biochemistry
departments at UCL and Sussex University. Finally, researchers from a government
research council, the Biological and Biotechnological Science Research Council
(BBSRC), responsible for reviewing the funding of bioinformatics were also
consulted.
Interviewees were contacted primarily by letter and then by telephone and E-mail to
confirm meeting details.   Interviews were scheduled at 45 minutes, however the
majority of interviewees generously gave additional time, exceeding 2 hours or more
in some cases.  Structured questionnaires were used as a basis for all interviews,
although interviewees were encouraged to speak more broadly in areas they saw to be
important.  Two slightly different questionnaires were used, one for pharmaceutical
firms and one for all others (see Appendix 2 & 3).
It is accepted that the views of those sampled may not reflect the views of the wide
range of organizations involved with bioinformatics.   Thus, every care has been taken
in the presentation of the data to avoid generalizations and assumptions based on the
opinions of a single individual or organization.  Additionally it must be noted some
questions asked could not be fully answered for reasons of commercial sensitivity.19
1.6.2 Secondary Data and Its Limitations:
Some firms involved in bioinformatics, including some of those interviewed have
published information about their bioinformatics programs or strategies.  This
information has been used to supplement interview findings.   In particular DBFs
involved in genomics and combinatorial chemistry have been keen to publish
accounts of their new technologies. However, it must be accepted that a number of
articles in this field are written more as advertisements rather than critical analyses of
the changing nature of technology in the drug discovery process.   In particular, care
must be taken to separate the facts from over enthusiastic hopes for which
biotechnology has become notorious.
The US Patent and Trademark Office database was also used to triangulate patterns of
firm activity in computational biology and chemistry apparent from literature and
interviews.  More detail on how these searches were carried out is given in Chapter 2.20
Chapter 2: Mapping Changes In Pharmaceutical R&D Processes
2.1 Introduction
The first key question introduced in Section 1.1, i.e. “how has bioinformatics been
integrated into the drug research and development processes of the firm” poses two
“hows”.  The first “how” relates to how new technologies sit within the existing
framework of drug discovery, and is of a technical nature.  The second “how” is
addressed in chapter 3, and relates to organisational issues.
This chapter introduces the nature of change in pharmaceutical R&D.   It identifies
broadly the areas where new technologies have allowed change and explains how
limiting factors in the R&D process have been affected.   These are related to specific
frameworks which authors have previously developed to describe the R&D process.
2.2 Traditional Routes to Drug Discovery
Discovering a compound with therapeutic effects in animal models either from
random screening or from clues given from traditional remedies used to be the
classical route to drug discovery.  This route has been used since the “golden age” of
the 1950’s and 1960’s.   The main competencies involved were chemistry and
pharmacology.  Finding targets, i.e. the point at which therapeutic agents should
intervene for treatment of a disease, would be the limiting step.  Close integration of
pharmacological and chemical competencies were needed as candidates for lead
compound selection underwent validation
47 and toxicology tests before being passed
on to wider trials.  Often firms would accept targets derived from animal models
48
developed outside the firm, from universities or other research organisations, although
other stages of the process would be continued in-house
49.  An additional limiting step
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is identified by Jean
50, who notes the average organic chemist could synthesis only
50-100 compounds per year for testing, against the limited targets available.  These
constraints governed that the overall process was low throughput.
All the integrated pharmaceutical firms interviewed previously subscribed to this
methodology, although they noted that the process did not always begin from the
same stage, and one firm stated their discovery program previously had concentrated
on “busting patents” of other firms to invent new patentable versions of existing
drugs.  This was and still is a common strategy, with lower risk of failure.  The so
called “me too” strategy is used to highly profitable effect in Japan’s pharmaceutical
industry
51.
 2.3 Present and Future Routes To Drug Discovery
As new molecular biology and genetic techniques have become available these have
been integrated into the R&D process, along with increasing drives towards
automation of target searches and screens. Figure 2.1 below gives an indication of
how these new and old processes fit together in drug R&D programs. Figure 2.1
shows some new technologies, in red text, appearing to enter the process.   Although
this process seems linear and continuous, the odds of a newly found molecule making
it through all these stages and becoming licensed for therapeutic use are slim, at 5,000
to 1, and 80% of leads entering development fail during clinical trials
52.  Drug
discovery had traditionally begun with an animal model of disease, which might be
used to yield a target.
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52 Anon, (1997) Testing, Testing, The Economist Vol.342, 1
st February  p.184722
However the advent of genomics has reversed this process.  Instead a target can be
found through DNA sequence analysis, and animal models are only introduced




Exploratory          Target Identification Screening Project
- Literature          -Biochemistry -Assay design -Chemistry
-Basic Biology          - Structural studies -High Throughput - Lead Optimization
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Over a period of many years and costing tens of millions of pounds
Development:
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- pharmacokinetics




Source: p.56 Lyall, A, “Informatics – The Key to redesigning Drug Discovery” European
Biopharmaceutical Review, March 1998.23
later. This has moved the focus of the R&D process away from developing animal
models as a primary route to establishing targets. Firms may now identify many
targets first and then choose which ones they which to validate and pursue. All firms
interviewed have developed competencies in molecular biology over the past decade.
It is now widely acknowledged as a core competency
53.  However, the degree to
which firms are accepting other changes seems to vary.  Firm A and Firm B have
begun to restructure their whole drug discovery programs around genomics (providing
targets), combinatorial chemistry and high throughput screening (selection of leads to
act on these targets).  They have both invested heavily in bioinformatics professionals
to support these new systems with an IT infrastructure that facilitates the highest
possible throughput of targets and drug candidates.   Firm C and Firm D have been
more cautious in their approach.  This is reflected in their smaller bioinformatics staff
numbers (figure 2.2) and by the continued use of traditional techniques.  However all
firms interviewed do use bioinformatics substantially to mine DNA databases for
targets.
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Figure 2.2 Table Showing Selected Interview Results
Name
Firm A
Firm B Firm C Firm D Firm E
Size Large Large Large Medium Small
Description Pharmaceutical firm Pharmaceutical firm Pharmaceutical firm Pharmaceutical firm Drug Discovery
R&D spending
 54 $1,830 million  $1,270 million $1,522 million  $45 million $15.5 million
R&D employees
55 10,000 5000 1800  - 60
Dedicated
bioinformaticians
up to 60 up to 70 12  up to 5 3
External data bases
mirrored on site
Yes Yes Yes Yes No
                                                          
1& 
2Based on 1997 annual reports
  25
Figure 2.2 also shows that in the search for targets all firms interviewed, except Firm
E, own copies (called mirror sites) of private and public databases which are kept in
house for several reasons:
·  In house database searches may be faster, without traffic problems/ busy lines
·  Searches and areas of interest are hidden from the view of outsiders
·  It is widely felt that those who can afford to buy material should do so to support
academic research.
Such is the demand for genomics data of this kind, Incyte Pharmaceuticals Inc. (US)
have sold subscriptions worth millions of dollars to 17 firms including six of the top
ten pharmaceutical firms (as measured by sales in Scrip magazine, January 1997).
These subscribers include two of the three large firms interviewed. However with
academic databases growing, and search strategies improving Firm B has recently
cancelled one similar alliance with Human Genome Sciences.   Figure 3.2 shows the
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Figure 2.3 Future Projection of DNA Bases stored on Genbank Based On
Previous Growth
Source:  p.929, Anon , Business and regulatory news, Nature Biotechnology, Vol. 15 No.10, 199726
Figure 2.4 shows the increasing number of “hits” from individuals visiting the
SwissProt on-line database, where protein sequence and structural information can be
obtained.  Although these hits presumably do not include searches made on mirror
sites in large firms, it does show the growing importance of remote sources of data in
biological research related to drug discovery.






































Source:  p.1255 Sansom, C, Finding A New Language For Bioinformatics, Nature Biotechnology, Vol. 15
No.12,1997.27
Interviewees confirmed remote data as becoming increasingly important in the early
stages of drug discovery.  In particular, it was highlighted searches may negate the
necessity to perform many experiments, as the experiment may have been performed
elsewhere, and results might be available through on-line searches
56.  Also the
importance of good informatics for literature searches should not be overlooked
57.
Increasingly journals are available in electronic form, and where they relate to
sequence or structural findings, these may not even be published in hard copy at all.
Electronic resources dramatically reduce the amount of time staff have to spend on
basic literature searches, and allow access to a growing volume of material otherwise
unreachable. Genomic and proteomic databases are interrogated using a variety of
software tools, available through academics (usually for a small license fee), software
suite suppliers (eg. Genetic Computing Group, GCG, and Molecular Simulations Inc,
MSI), consultants, and in-house development.
Further variations in firm strategies are apparent from the ways in which firms use
these software tools.  Whilst all interviewed firms have these tools available to all
research staff on intranets or local computer terminals, only Firm A and Firm B are
attempting to integrate the tools themselves.   By doing so, they hope to make them
more user friendly, give them wider scope, and allow the smooth transition of data
from one system to the next.  This should allow the comparison of large complex data
sets automatically where other firms make do with manual comparison.  This should
allow unique insight and understanding of the biological systems they research, which
might be missed by those using non-integrated systems.
 Whilst genomic data is mainly used for finding targets at present, proteomic data and
structural data relating to small molecules, may be used later in the R&D process, for
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rational drug design, where models can be used for docking studies of drugs and their
points of action.     Once a target has been identified, screens and rational drug design
are used to produce a lead candidate molecule that acts on it.
Nightingale has put forward a framework that takes into account new technologies
which allow higher throughput of more effective candidates  (figure 2.5) where
rational drug design is applied as well as combinatorial chemistry to optimise leads.
Another author, Jean, demonstrates how the stages Nightingale identifies as d) and h)
can be run by HTS and combinatorial chemistry combined with robotics and
bioinformatics once a target has been identified by stages a) and b).  Importantly,
Jean’s Model (see figure 2.6) also reflects the non-linearity of the R&D process,
which Lyall’s macroscopic overview does not focus on.  Firm E’s principle scientist
also emphasized the starting point for projects may differ on a firm by firm or even a
case by case basis
58. Jean indicates the stages in which robots are used to facilitate
high throughput (in blue). Robots necessitate the use of complex data handling
informatics to support them.  The processes set out by Jean are not the universal
choice for the firms interviewed.  Firm A and Firm B seem to be heading towards
Jean’s route, whilst others have been more cautious in their approach to combinatorial
chemistry.
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c) Generate assays from Proteins
e) Find 3 D Structure
f) Characterize active site
g)Rationally Select & Test
a) Basic research
h) Optimise lead compound
i) Pass compound on to clinical trials
b) Select functional protein
“Rational drug design” “combinatorial chemistry”
d) synthesise and test diverse
population
Figure 2.5 Nightingale’s Model of Drug Discovery
Source: p.122, Nightingale, P (1997) Knowledge and Technical Change: Computer Simulations and the
changing Innovation Process, University of Sussex30
Figure 2.6 Jean’s Model of The New Drug Discovery Process
Source: p.37 Jean, T, Drug Discovery in Contract Research Organisations, European Pharmaceutical
Review, September 1997
Firm D mentioned they could always outsource this capability in the future, as there
seems to be a growing number of firms specialising in this area.   They went on to
reveal they are continuing to use the low-throughput traditional methods
59.
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Target Identification (increasingly more through geneomics)
Assay Validation (using molecular biology techniques)
Combinatorial Chemistry (large and diverse libraries)
High Throughput Screening
Hit Selection




Combinatorial Chemistry (focuses libraries)31
Figure 2.7 shows the cost saving and higher rate of throughput allowed by
combinatorial chemistry.






Total cost $30,000 $40,000
Cost per compound $7500 $12
Source: p.691, Persidis, A, Combinatorial Chemistry, Nature Biotechnology, Vol.16, July 1998
Nightingale provides further evidence of the integration of combinatorial chemistry,
in this case being used in Zeneca (not interviewed). Here combinatorial chemistry has
allowed screening to increase from 160,000 compounds over 16 years leading up to
1992, to 500,000 compounds a month in 1995
60.  Lyall (figure 2.8) has predicted how
the R&D processes may look in a typical fully integrated pharmaceutical firm of the
future, both upstream and down stream of the areas Jean’s model focuses on.   
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Figure 2.8 Lyall’s Vision of Future Drug Discovery
Preliminary Investigations
·  Data retrieval over internet
·  Database integration
·  Alerting systems
Target Identification
·  Genetics
·  Molecular biology
·  Sequence analysis
·  Assay design
Target  Validation
·  Modeling of pathways
·  Simulation of biological processes
·  Differential gene expression
Screening
·  Screen design
·  Combinatorial library design
·  Compound set Selection
Rational Drug Design
·  Protein Structure computing
·  Integration with Small Molecule database
Source: Lyall, A, (1996) Bioinformatics in the Pharmaceutical
Industry, Trends In Biotechnology, vol.14 p.308-312
Key:
Blue - computer based
activity
Green – laboratory based
activity33
If all the technologies shown in figure 2.8 were established in house, then around two
thirds of the stages listed would be carried out on bioinformatics systems. Firm A and
perhaps others aim to integrate as many of these as possible.  Thus it would be
conceivable in the future for a researcher to identify a target gene, find its sequence
and predict a likely structure for the protein it represents, and then find a family of
compounds likely to show activity on the protein, without leaving their computer
61.
Others take the view that this is unlikely for many years, if it becomes possible at all
62
because the very slow X ray-crystallography technique is currently the only accurate
process that can predict protein structure, and computer modeling may never be
sophisticated enough to replace this technique entirely. However X ray-
crystallography can be used to study homologies between structures, which can then
be related to sequence data through infomatics.  Thus the exact structure may not be
known but a “best guess” may be available and this will be enough to bias screening,
saving valuable resources
63.
2.4 Changes In The Limiting Step of The Drug R&D Process
Even though full integration has not been reached, the limiting stage of the discovery
process has already been changed in many firms.  The majority of interviewees in
firms and academia see validation and “wet biology” as continuing to be a limiting
step.  In the validation stage molecular biologists must demonstrate by experiment
that acting on the protein or gene selected will have the desired result, and once a lead
compound has been found through screening, testing it in an animal model will also
prove to be a limiting step.  B1 described these stages as “bespoke biology”, with no
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short cuts as yet, although other interviewees hinted that a degree of computer
simulation might be applied in these areas in the future.
The overall effect of these process changes has been to greatly reduce the time taken
for a research project to move through its initial stages, and for the volume of leads
generated to increase. However, the leads may be more numerous, but they are not
necessarily of as high quality (likely to succeed) as leads developed through
traditional processes
64.  Another bottle neck interviewees agreed on was the boundary
between research, where a candidate for trials is discovered and optimised, and
development, where the candidate is prepared for scaled up production and tested in
clinical trials.  At this stage candidates may fail simply because the cost of mass
producing them is uneconomical
65.  Furthermore trials are very expensive to run, and
so only the highest quality candidates are entered into this process.  Failure at a late
stage in trials may cost a firm tens or even hundreds of million dollars. Figure 2.9
shows roughly the cost structure of the whole R&D process. Cost on the diagram is
not indicated as a figure, due to the variability of this between projects and firms. The
important point to note however, is the tiny proportion of cost spent on research,
where all the process innovation and bioinformatics developments discussed here is
incurred.  The overall cost per drug on development is not expected to fall as a result
of bioinformatics, or other new technologies used. The cost saving should result from
the greater knowledge of targets and candidates, and knowledge metabolic pathways
surrounding them, which will allow researchers to select candidates more likely to
pass the gauntlet of trials successfully and thereby reduce the numbers of costly
failures.
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Figure 2.9: The Cost Structure of Bringing a New Drug to Market
Source: adapted from a sketch by B1 at Interview
It should also be noted that bioinformatics or other new technologies are not expected
to reduce the time it takes to bring a compound through the development stage.  The
clinical trials structure must adhere strictly to regulatory guidelines, and so the trial
periods are not flexible.
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Chapter 3:  Strategies For Managing The Growth of New Technological
Competencies In Bioinformatics
3.1 Introduction
This Chapter addresses issues related to the second key question posed in section 1.1
which was: what strategies have pharmaceutical firms used to acquire capabilities in
bioinformatics?  Additionally, the organisational issues surrounding the first key
question of “how bioinformatics has been integrated into the pharmaceutical R&D
process” are also addressed.
The findings of interviews conducted on the cross sectional group of firms, academics
and others mentioned in section 1.6, as well as data from secondary sources are
examined in relation to notions in the technology strategy literature. These notions
relate to the development of technological competencies and the maintaining of
competitive advantage in firms.
3.2 A Review of Frameworks Used
Three theoretical frameworks from technology innovation management literature are
referred to in support of the argument outlined in Section 1.2.  The key points relevant
to this study are outlined here.
3.2.1 Autonomous and Systemic Innovation
Chesbrough and Teece
66 examine the notion of outsourcing, and propose a framework
to determine when “virtual” organisations networked to external competencies might
succeed over less flexible larger organisations.  They identify two type of innovation,
autonomous and systemic.   Autonomous innovations can be used without effecting
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other surrounding systems (e.g. The introduction of a turbocharger for a car engine
does not require the rest of the engine to be designed). On the other hand systemic
innovations have complex effects on surrounding systems when they are introduced
(e.g. when Polaroid introduced their new film, it needed a new camera to support it.)
Chesbourgh and Teece propose that if the technology desired exists outside and is
autonomous in nature, it may be suitable for outsourcing where as technologies that
must be created, and are systemic should be developed in-house to ensure they are
compatible with other systems.  Figure 3.1 demonstrates the choices facing a firm,
and the suggested action to take.






           Go virtual     Ally with caution
Capabilities needed must
be created
    Ally or bring in house         Bring in house
Source: p.73 Chesbourgh, H, & Teece, D (1996) When is Virtual Virtuous? Harvard Business Review,
January –February38
3.2.2 Multi-Technology Firms and Distributed Competencies
Granstrant, Patel and Pavitt
67 describe multi-technology firms as having distributed
competencies, often broader
 than represented by their products.  Furthermore they
maintain that over time it becomes necessary to develop new technological
competencies to provide the driving force for corporate growth, increasing R&D
investment, increasing external linkages, and allowing new technologically related
business opportunities to be grasped.   They argue firms developing these new
technological competencies firms should be wary of four previously accepted
management concepts.  These are:
·  firms should focus on their core competencies,
·  major new innovations often bring about “competence destruction”,
·  firms should downsize and outsource, and that
·  firms should specialize on a narrow set of core businesses.
In addressing these points, they highlight two methodologies for measuring
technological competencies.  One method is to measure the capacity of firms to
achieve a certain level of functional performance in a generic product or system.  This
method is difficult to measure by quantitative means, and so the authors chose to use
another methodology for their study, the measurement of patenting activity by
technology class as recorded in the US patent and trademark office database.
To identify and examine holders of technological competencies in bioinformatics, I
used the qualitative interview approach as well as attempting the quantitative patent
measuring approach, and the findings from these are discussed in section 3.3 and
section 3.4 respectively.39
3.2.3 Dynamic Capabilities and Competitive Advantage
Teece and Pisano
68 describe a framework of characteristics associated with firms that
possess what they call dynamic capabilities.  Dynamic capabilities refer to the
management strategy that allows certain firms to:
“reconfigure internal and external organisational skills resources and functional
competencies towards a changing environment”
Source: p.537 Teece, D & Pisano, G “The Dynamic Capabilities of Firms” Industrial & Corporate
Change, Vol.3 No.3, 1994, Oxford University Press.
The relevance of these capabilities to bioinformatics is that restructuring of core
processes within pharmaceutical firms is apparently occurring, to take advantage of
new technologies and overcome environmental pressures. Teece and Pisano explore
the theories of previous authors, who take the view that competitive advantage stems
from exploiting internal and external firm specific capabilities and developing new
ones.  They then examine how some firms are able to renew capabilities to adapt or
even capitalize on rapidly changing markets.  Although they identify factors important
to product innovation through times of environmental change, these factors are
equally valid when applied to process innovation in pharmaceutical R&D.
Teece and Pisano break down the relevant characteristics into processes, positions and
paths.
·  Processes focused on are organisational and managerial.  They relate to the firm’s
ability to  integrate, learn, reconfigure and transform.
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·  Position. The technological assets such as know-how or patents, complementary
assets such as distribution networks or customer relations, financial assets, and
even locational assets, i.e. geographical position.
·  Paths refer to the choices available to a firm for future development, which are
shaped by path dependencies and technological opportunities.  Path dependency
refers to the notion that firms previous experience helps or hinders them, thus
determining their options.  Not all paths will be available, due to core rigidities,
and firms may prefer to do in the future what they have done best in the past.  The
number and scope or technological opportunities available to a firm also depends
on the R&D capability it may posses, or links with external R&D.  Thus firms will
have different options open to them.
Teece and Pisano also suggest that the key to maintaining competitive advantage is
having a capability that is difficult to imitate, and is supported by intellectual property
rights.  Section 3.5 relates Teece and Pisano’s work to the development of
bioinformatics within the pharmaceutical industry.
 3.3 Assessing Competency In Bioinformatics Though Qualitative Information
From Interviews
Difficulty in establishing the existence of bioinformatics competencies in
pharmaceutical firms from patent data meant that more qualitative information from
interviews was required to identify the extent of expertise held by these firms.
Granstrand, Patel, and Pavitt identify four stages that lie in between full integration of
a technology and full-scale disintegration, where purchase of products or services
relating to a technology are produced externally.  By using these four stages as a41
basic scale it is possible to assign a rough quantitative measure to the progress of
interviewed firms in achieving a capability to create, integrate and use software tools.
The stages on the scale are:
1.  Full design capability – competency to design and test products comparable to
those produced externally for example the ability to design bioinformatics
software suites as available from specialist external suppliers.
2.  Systems integration capability – competency in integrating changes and
improvement in internally or externally designed or produced systems or products,
For example, the ability to modify software tools and integrate them together to
optimise their use within the firm.
3.  Applied research capability – competency to specify and purchase externally
produced products or systems, and to control changes and improvement relating to
them.  Thus the firm may have sufficient knowledge of software systems to allow
their use within the firm, and to modify or inform external suppliers how best to
modify tools to meet the firms’ needs.
4.  Exploratory research capability – competency in identifying and evaluating new
opportunities available from a new technology, and integrate new opportunities
with current activities, for example, recognizing the importance of bioinformatics
and being able to introduce some software tools to enhance R&D.
At interview questions were posed to establish which of the four stages firms intended
to reach and the strategies they used to achieve their goals with respect to
bioinformatics.
Questions posed are shown in fig 3.2.  It is clear that the firms have achieved differing
levels of competency, but identifying which of the four stages above they fit with best
is not straightforward.  Furthermore it must be accepted that firms seek to achieve42
different goals to meet their specific needs.  Whilst all interviewed firms seek to
discover new drugs, the therapeutic areas in which they hold expertise differ.  Thus
whilst a larger firm might be able to develop drugs in a number of therapeutic areas, a
smaller firm may only be looking for drugs to treat neurological diseases or
circulatory disorders in which they are specialised.  These factors inevitably effect the
strategy they might use to find and select targets, and in turn the types and
characteristics of the software tool they require to meet these needs.
Firm A and Firm B require a high throughput system to meet their target of producing
several successful new drugs each year. Thus both firms have invested heavily in
attempting to gain the capability to integrate existing systems and tools to compare
large and diverse data sets.  They also possess the capability to design their own tools,
however they still require software from external sources, and would be hard pressed
to design many of the products designed externally.  Thus they might be somewhere
in between stage 1 and 2 on the scale.  Pfizer has had some success with producing
software tools, but also uses many externally produced tools. However they are not
attempting the level of software integration planned by Firm A and Firm B, thus Firm
C might be placed slightly lower than Firm A and Firm B, but still between stages 1
and 2 on the scale.  Firm D and Firm E have more focused needs regarding drug
candidates, and are not seeking high through put integrated systems. Both use
externally produced tools. They do not produce their own software tools, although
they may slightly modify existing software to fit with their needs.  Neither firm has
plans to integrate tools in the way Firm A or Firm B propose.  Firm C and Firm D
would probably sit around stage 3.43
Figure 3.2: Comparing Competency Building Efforts - Selected Interview Results
Name
Firm A
Firm B Firm C Firm D Firm E
Years since entry into
bioinformatics
10 years 7 years 6 years 3 years 3 years
Training courses in
house












Yes Yes Yes No No
Identified  a shortage
of
bioinformaticians
Yes Yes Yes - Yes44
  Elements of strategy used by these firms to build up their competencies were also
identified (figure 3.2).  The pattern and approach to recruitment of dedicated
bioinformatics staff, mainly from academic backgrounds, is a clear indicator of how firms
see bioinformatics changing the R&D process internally.  Firm A and Firm B have
established internal bioinformatics training programs to facilitate the learning of new
techniques amongst the bench scientist user community.  However at the other end of the
size scale, Firm E take the view that such programs are not necessary due to the more
effective diffusion of such tacit knowledge through a small and informal firm, which also
has close links to the near by University.  Other indications of competence building are
shown by efforts to enter co-development with suppliers of software solutions, such as
alliance Firm A has with Oxford Molecular in which several Oxford Molecular staff
work within the firm semi permanently. Firm D and Firm E do not have such alliances
and are content merely to use existing tools, although they may co-operate with suppliers
of software solutions in testing and feedback exercises, which might result in favourable
licensing agreements later on.45
Figure 3.3 summarizes the grades firms have been given on the scale and the key reasons
for placing them accordingly.
Figure 3.3 Grading Interviewed Firms By Competency in Bioinformatics












Firm C Relatively long presence
Medium resource commitment
Developing software in house
Not attempting systems integration
No co-development




Not developing software in house
Not attempting Systems integration
No co-development
It appears there are few initial barriers to firms wishing to use bioinformatics. Indeed
academics interviewed stressed the ease for firms and academics to access these tools and
techniques with relatively small budgets, although firms would have the added expense
of greater licensing fees.  One barrier widely noted and revealed in figure 3.2, was the
shortage of bioinformatics staff.  One firm questioned was in the process of poaching
staff from other firms at the time of interview.
To summarise, the evidence from interviewees suggests bioinformatics can be accessed
relatively easily at a basic level.  However, beyond this level, and surrounding the task of
integrating tools and changing R&D processes more significantly, more complicated
barriers and questions are raised.  A greater level of competency may be required to
derive further benefits from bioinformatics and gain a competitive advantage from it.46
The numbers of staff and many years Firm A and Firm B have allocated to the task are a
clear indication of this when compared to the numbers of staff Firm C use.  Granstrand,
Patel,  and Pavitt state:
“The effective use and improvement of outside components, sub-systems and machinery
requires a matching in house capability to choose, integrate and learn as well as to co-
ordinate and manage systematic change.”
Source: p.11 Granstrand, O, Patel, P, & Pavitt, K (1997) Multi-Technology Corporations: why they have
Distributed rather than distinctive core competencies, California Management Review, Vol. 39, No. 4.
It has become clear that Firm A and Firm B have attempted to integrate bioinformatics to
the extent that it is not just a set of additional tools at the fingers of bench scientists.
They intend to re-design the entire R&D process around a set of technologies geared
towards making the whole R&D process a high throughput drug discovery search.
Whilst the changing technological aspects of the R&D process were considered in
Chapter 2, the ensuing organisational implications are considered in section 3.5 and relate
to Teece and Pisano’s notion of dynamic capabilities.
3.4 Assessing Competence In Bioinformatics Through Patenting Activity
Granstrand, Patel and Pavitt identified distributed competencies in multi-technology
firms by using patent data to show specific fields of technology in which firms were
active
69. To further support the interview findings, I carried out a patent search to identify
firms actively patenting in bioinformatics.
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3.4.1 Search Methodology:
Searches for patents were carried out on the US PTO web site, rather than on SPRU’s
Megatech database, because the window of time requiring examination includes resent
years not recorded on the Megatech database which contains data only up to 1994.  Due
to the fact bioinformatics is a relatively new field, most relevant patents are post 1994.    
Relevant patents where found by searching for those which fell into both chemistry and
computing classifications.  Patents thought to be appropriate were found by a search of
several classes
70 from 1990 to the present day.
3.4.2 Limitations:
It is not clear whether the search has “hit” every bioinformatics related patent in the
database, as other relevant classes or even sub classes may not have been searched.
However, it appears that a sample of patents in this area are available to make some
analysis of activities in the field.
3.4.3 Results:
The search yielded several hundred hits, and the abstracts were examined manually.
Only those relating to DNA analysis, protein modeling, rational drug design or
combinatorial chemistry databases were useful for the purpose of this study.  However,
many of the discarded patents show the increasing use of computers in biological and
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chemical research, particularly in the areas of automated laboratory processes and
detection/ screening systems, but not necessarily those linked to drug R&D.
The 27 patents remaining where held by firms, individuals and universities in the
proportions shown below in figure 3.4.
Figure 3.4 Assignees of Bioinformatics Related US Patents From 1990 Onwards
Assignee type Number of patents held
Large Firms 4
SMEs 13
Universities & Research Organisations 5
Individuals & Others 5
The large firms were the Japanese firm Hitachi (1) US firms IBM (2) and Perkin Elmer
(1).
The SMEs were all of US origin, and included 3-D pharmaceuticals (2), Cirrus
Diagnostics (1) DNAstar (1), Genex (3), Immunex (1), Ironi (1) MCC-Molecular
Simulations Inc. (1) US Biochemicals Corp. (2), and Visible Genetics (1).
Additional searches for interviewed firms by name did not reveal any patents in fields
relating to bioinformatics.
3.4.4 Discussion of Patent Search Results:
Integrated pharmaceutical firms, known from interview to be carrying out work in this
field have not been shown to have a competency using the internet patent search
technique.  When questioned about patenting in the field of bioinformatics, some firms
declined to answer and others mentioned the information sought was confidential.
However, it must be accepted that patenting in this field would concentrate around49
software protection, and this is an area of known weakness in the patenting system
71.
One firm specializing in this area, Oxford Molecular, indicated they generally use trade
secrets as their primary means of intellectual property protection because of the ease with
which software patents can negated
72.  Another possible reason for the lack of patent
protection on work in this field is that firms may be creating software tools or links that
address problems specific to their own bioinformatics programs.  These might not be of
use to other firms, as each sub-system created is likely to be unique and of little use to a
competitor without copying the system as a whole.  The so-called “embedded software”
73
created by such activity is therefore not patented because firms are not concerned about
competitors imitating it, unlike software designed as a commercial product.
Firms who are patenting in the field seem to be almost entirely from the US, which is
where many of the bioinformatics developments began in universities.  Although large
integrated pharmaceutical firms were not represented in the groups above, it is known
from interview that the distribution of their staff working in bioinformatics also reflects
the US is leading other regions in terms of bioinformaticians, just as it did with molecular
biologists some years ago.  This, coupled with the US entrepreneurial culture seems to
have lead to the formation of several firms apparent in the search results, who specialize
in bioinformatics software tools.  Possibly because these tools are produced for use in
external organisations, these firms are more likely to try to protect their intellectual
property with patents.
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Also present in the results are Hitachi and IBM.  Both these firms have patent portfolios
that are broad and reflect their exploratory nature.  Given their existing competencies,
electronics and IT firms may be well placed to grow development capabilities in the area
of bioinformatics, and these exploratory patents may indicate a future interest in working
in this field as suppliers of software solutions to the pharmaceutical industry.  In
conclusion it seems the patent search methodology has limitations, and technological
activities of firms can remain hidden unless they choose to disclose these in interview or
by publication.
3.5 Assessing The Role of Dynamic Capabilities In Allowing Firms to Integrate and
Derive Competitive Advantage From Bioinformatics
The findings of section 3.2 show distinct differences between the approaches of the
interviewed firms towards bioinformatics.  By using Teece and Pisano’s framework it is
possible to see which firms exhibit strategies characteristic of firms with dynamic
capability and how bioinformatics creates competitive advantage.
Processes:
Integration: Of the interviewed firms, Firm A and Firm B have made considerable financial
effort to facilitate the integration of bioinformatics into R&D.  In Firm A this process
began over ten years ago, with a plan set down for steady organic growth of
bioinformatics related capabilities, in contrast to the rather rapid response Firm B made
several years later.  Infrastructural changes needed for the integration of these tools were
established with a computer infrastructure (and one of the first intranets in the
pharmaceutical industry) data management systems, and layers of information systems
which would eventually support the bioinformatics systems.  Firm B has also spent51
several years on what Director of Bioinformatics for Firm B, interviewee B1, describes as
“ground work”.   The other firms interviewed had not spent as much time or resources on
this infrastructure, although they had all built intranets.  According to researchers,
without integration of tools and packages associated with bioinformatics, data  becomes
balkanized
74.  The result is data collected forms into islands and may be under-utilized
and even need to be re-created on a different system before it can be used.  Such islands
can form as a result of poor planning as well as due to software incompatibilities
according to a Bains
75.  To avoid these problems in the future, SB has been careful to
leave “threads” to link databases, and has worked with consultants to develop software
termed “wrappers” which can be used to move information between systems that cannot
understand each other.
Learning: Learning processes are also very important when trying to gain new
competencies, especially where software skills are involved. These are notoriously
difficult to learn from a book, and tend to be learnt best “by doing”, i.e. a personal
process of trial and error. Indications in 1996 where that only 10% of Firm B’s scientists
were using bioinformatics tools available to them effectively
76. However some firms are
attempting to solve these problems and as mentioned in section 3.3, Firm A and Firm B
have established in house training, whilst Firm C and Firm D train staff through external
courses.  But training courses may not provide an effective route in all firms, as Firm E’s
principle scientist, E1 noted.  He prefers his staff to experiment and teach each other.
Evidence from some interviewees also suggest that resistance to change amongst bench
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scientists may be strong in some firms, and at least one large firm was indicated to be
developing cultural problems between bioinformaticians and other research staff.  This is
partly because of problems in semantics between groups of individuals from very
different scientific backgrounds, and partly because of a feeling of being “devalued”
which is said to be spreading through molecular biologists, who might feel
bioinformaticians are unduly influencing their research
77.
Reconfiguration and transformation in the R&D process have been discussed in Chapter
2, where it was highlighted Firm A and Firm B are attempting to substantially change
their R&D processes whilst other firms are not.  Bains notes some firms may be
dissuaded by the costs of software, support systems, time and other resources that may be
difficult to justify as future gains resulting are still uncertain
78.  Additionally for firms
such as Firm C, it seems traditional methods are still yielding results
79, and a more
cautious approach than Firm A and Firm B has been adopted as a result.  However, being
slow to adopt may also be a risky strategy.  Teece and Pisano point out that timely
response and rapid and flexible innovation are important in maintaining dynamic
capabilities.  Certainly, bioinformatics is a very fast moving field at present, and given
the time taken by Firm A and Firm B on groundwork, firms which are slow to respond
may find themselves left behind.  Janet Thornton (University College London) noted
much of the best expertise has already been hired and firms now developing capabilities
may have trouble finding good staff.
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Positions:
Technological assets: Many of the technological assets important for utilising
bioinformatics do not have to be developed in house.  However, buying in technology
does not always work, as some firms may find they cannot use the technology
effectively
80.  Interviewees from more than one firm indicated technical support offered
by software suppliers was generally inadequate to support firms without internal know-
how.  As the data from Section 3.4 shows pharmaceutical firms do not seem to be
developing patented technological assets in this field, but the assets they are
accumulating may be non-transferable and difficult to replicate because they are tailor-
made to work on internal systems.
Complementary assets: Established pharmaceutical firms have complementary assets
such as the ability to run clinical trials, as well as distribution and sales capabilities which
are necessary to derive benefit from strong R&D capabilities.  Bioinformatics does not
devalue these capabilities nor does it enhance them.  Therefore firms that do not already
possess these assets do not threaten the position of established firms by developing
bioinformatics.  Indeed it is partly because of these complementary assets that
biotechnology firms previously hoping to become fully integrated pharmaceutical firms
have often had to rely on established firms to help them bring their products to market.
Financial Assets: Bioinformatics and other new technologies being integrated into
pharmaceutical R&D are expensive, and only firms which devote large amounts of funds
can generate the tailored systems Firm A and Firm B are attempting to create.  However,
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large pharmaceutical firms are generally in a position to make this level of investment if
it is required.  It is smaller firms for which this may prove to be a problem.     
Locational assets: Even in an age of globalised R&D, and remote databases accessible
through the internet, location can still be of great importance.  Interviewee E1
emphasized this point as he pointed out many of his research staff come from laboratories
around Cambridge, and their proximity allows them close links to developments in the
academic community there, as well as access to tacit knowledge.
Paths:
Path dependency: Although bioinformatics may help firms to discover new drugs, it does
not replace the other capabilities needed in the research process.  Therefore only firms
with experience of fields such as pharmacology, molecular biology, organic chemistry
etc. will be able to benefit from bioinformatics.  Furthermore, firms that have not been
successful in integrating other recent technologies are less likely to benefit from
bioinformatics.  Some firms may even be less inclined to attempt integration because of
limited success in the past with chemi-informatics
81.
Technological Opportunities: These are available in broadest choice to firms with in
house R&D in the relevant fields, and to those who have alliances or links to external
groups also working in similar fields.  Interview findings show that all three large firms
interviewed are innovating in the field, creating new tools and thus opportunities to make
better use of the available data than firms simply buying in tools.  Firm A and Firm B
also have extensive links with consultant firms and universities.  Firm C are not using any
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consultants at present. They have however worked closely with Incyte Pharmaceuticals,
and receive preferential treatment to other licensees of Incyte’s products as a result
82.
Therefore large firms appear to be in a better position to make use of the technological
opportunities made available by integrating bioinformatics into R&D processes.
However as yet the advantages of using bioinformatics are unproven, and no drugs yet
licensed are the product of genomics or combinatorial chemistry, two key technologies
made accessible through bioinformatics.
Competitive Advantage and Apropriability Regimes:
Of the firms interviewed, only Firm A and Firm B made a specific point of stating
bioinformatics will give them a competitive advantage.   The basis of this competitive
advantage will be the integration of bioinformatics tools with each other to allow data to
flow between systems, and thus complex analysis will be possible more easily, and will
produce more valuable research as a result
83.  Teece and Pisano suggest this ability
becomes a distinctive competency of competitive advantage if it is hard to replicate and if
the intellectual property upon which it is built is easily protected.   From the limited
information available from interviews, it does seem that such a bioinformatics capability,
in its most developed form would indeed be very hard to replicate, and thus could make
bioinformatics a core competency of strategic importance, and providing competitive
advantage.  However, even the most advanced systems available to large pharmaceutical
firms are far from completion at present.
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Chapter 4: Conclusions  
4.1 The Changing Nature of Pharmaceutical R&D
In this study an insight has been gained into the changing nature of pharmaceutical R&D
processes, as effected by bioinformatics and a host of other new technologies and
environmental factors. Developments in a number of fields including molecular biology,
cellular chemistry, combinatorial chemistry, high throughput screening, structural
biology and computer based information handling systems offer new opportunities to
streamline in-house drug R&D.  Bioinformatics is key to unleashing and optimising
research results from waves of complex data generated by these new fields of research
and stored in large databases, available internally, and externally from private and public
sources.   Interview findings show bioinformatics is being used almost universally in
pharmaceutical firms.
At the same time internal and external pressures are forcing change in the way R&D is
carried out within the pharmaceutical industry. The overall cost of R&D has been steadily
increasing as regulatory guidelines tighten.  New developments in the field of
biotechnology centered around the activities of DBFs and universities have forced
pharmaceutical firms to form complex webs of alliances in order to access new
technological fields.
4.2 Review of  How Theoretical Frameworks Relate To  Key Findings
This study has addressed the questions: what strategies have pharmaceutical firms used to
acquire capabilities in bioinformatics, and how has bioinformatics been integrated into
the drug research and development process of the firm?57
Interview data collected from pharmaceutical firms, DBFs, bioinformatics consultants,
and university departments as well as secondary data sources, supports theoretical
frameworks relating to innovation by firms in new technological fields:
·  Large firms attempting to benefit from tailor-made integrated systems have found in-
house capabilities must be created to support bioinformatics because of the systemic
rather than autonomous nature of the complex software infrastructure required, as
theorised by Chesbourgh and Teece (1996). Whereas firms using software tools in a
piecemeal fashion do not require as substantial capabilities in house, as the tools fit
more with the autonomous model Chesbourgh and Teece put forward.
·  Firms seeking innovative design of their R&D processes are forced to develop
capabilities (i.e. software development) beyond those represented in their products, as
suggested by Granstrand, Patel, and Pavitt (1997). Without this capability firms are
less able to direct innovation of software, in-house or from specialist suppliers, and
therefore less able to exploit other related platform technologies such as genomics.
·  Teece and Pisano (1994) demonstrate the importance of paths, positions and
processes in allowing a firm to derive benefit from technological change.  The
characteristics they identify as significant have been examined in firms interviewed,
demonstrating areas of strength and weakness.  Most crucially, Teece and Pisano
maintain competitive advantage is best kept by demonstrating difficult to replicate
competencies.  The ability to create integrated bioinformatics systems is
demonstrated by interview data to be a highly complex task, requiring much
investment of time and resources. Furthermore the resulting system is tailored to user58
requirements and so even direct imitation may not allow a competitor similar
advantages.
Additionally the frameworks set out by Granstrand, Patel, and Pavitt (1997) have allowed
a scale to be applied to qualitative data to grade firms’ comparative competencies, in the
absence of sufficient quantitative data such as patent statistics.
The scale identifies a continuum of competency levels in interviewed firms, from which
two distinct groups emerge. Whilst some firms are using bioinformatics as additional
tools in a piecemeal manner and at relatively low cost, other firms are attempting to
integrate bioinformatics tools into tailored systems allowing more complex analysis of
separate data sets automatically, that firms without integrated systems can only manage
manually.
The development of the two groups is partly due to the bioinformatics requirements of
interviewed firms being different, however factors such as cost and risk also play an
important role in dissuading some firms from following the route to full systems
integration.  Some pharmaceutical firms such as Firm D
84 and Roche
85 (not interviewed)
are content to limit the extent of in-house expertise in favour of outsourcing to Contract
Research Organisations, even in traditionally key areas such as drug discovery and
screening.  Where such moves are considered as an alternative to maintaining in-house
capabilities, they should not be confused with alliance formation, often used to boost
internal capabilities in the long term. Instead this outsourcing should be seen as a cost
cutting measure, chosen simply because external organisations offer a cheaper
alternative.  These pharmaceutical firms may choose to focus on their core competencies
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for reasons of cost.  However, such firms risk reliance on firms in the DBFs sector to
supply targets or leads for research.  For example, a pharmaceutical firm might continue
to run clinical trials and outsource research instead of broadening their competencies in
new platform technologies such as combinatorial chemistry or bioinformatics.  However,
technological changes have not resulted in competence destruction, as predicted by early
DBFs and hopeful venture capitalists.  Instead firms with strong competencies in
pharmaceutical R&D will now have the opportunity to develop new competencies and
enhance their R&D.  A number of these firms are attempting to integrate new techniques
to maintain as much of the R&D process as possible in-house
86.
Interview evidence has shown the initial barriers to entry for bioinformatics are relatively
low in the experience of firms and academics using the piecemeal approach to derive
localised benefits to researchers. However staying up to date and developing robust
systems to quickly interpret fast changing sources of information, and to act as a platform
supporting the backbone of a research program in a large firm is proving more a costly
and complex problem to address.   This form of integration is much more complicated to
manage, and requires a higher level of time commitment and resources.  The resulting
tailored systems take many years to develop, will be hard to replicate externally, and thus
may become a source of competitive advantage as suggested by Teece and Pisano’s
framework. Firms attempting to follow this path, such as Firm A and Firm B view
bioinformatics as a new core competency necessary for maintaining pharmaceutical
product pipelines at affordable levels as well as a source of competitive advantage.
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4.3 The Impact of Bioinformatics: Benefits and Limitations
Bioinformatics will enable R&D staff to use a wealth of new information to make more
informed choices at a number of stages in the research process.  This should result in
stronger candidates entering the expensive human trials stage, with less likelihood of
costly failure resulting, according to interviewees
87 and as argued in Section 1.2 of this
study.  Additionally, when integrated these new tools will allow the faster progression of
initial phases of research, thus the volume of candidates developed will increase.
Optimizing the use of information that bioinformatics provides will derive future
competitive advantages for firms with more advanced systems, whilst firms without such
systems may be less able to produce high quality candidates at high rates, and will still
face increasing financial pressures as discussed in section 1.5 .
As a result of bioinformatics, the focus of initial research has moved away from
traditional methods. The computer becomes a vital part of the research process right from
the outset, providing details of external research quickly via the internet, and  allowing
targets to be found from data mining in sequence databases.  The growth in targets and
the speed of screening has lead to a change in the limiting factors in drug R&D processes.
These are expected to remain in the areas of “wet biology”, where real experiments are
needed to validate findings from computer based research. Optimistic researchers at firms
such as Pharsight, and MGA (both US SMEs) see   even these bottlenecks reducing in the
future through advanced simulation techniques
88. However, it is still debatable as to
whether further software developments will allow the simulation of findings from x-ray
crystallography and drug metabolism studies.    Although research projects may move
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more quickly through their early stages as a result of bioinformatics and other new
technologies, development processes will remain largely unaffected by these changes.
Rather, hopes for reducing development times lie with the FDA, who after pressure by
US Congress are allowing new rules for rapid progress of certain drug through trials.
One example is Saquinavir, an AIDS protease inhibitor
89, which was passed in under
three years of trials as opposed to the average 7-9 years, and licensed in less than 100
days (less than a third of average licensing time).  This was facilitated by the introduction
of  “surrogate” end points in trials, predicting improvements in the long term through
milestone changes over short time periods.
Although much work is being undertaken in-house by large pharmaceutical firms, the
academic community has been the major contributor both of software and expertise in
bioinformatics.  The availability of some software for free or at little expense from the
public sector has facilitated firm’s entry into this area at low cost.  More costly
commercial software houses and consultants also contribute to the supply of tools
available to firms.  These are often provided with more robust, user-friendly interfaces
and integration mechanisms.  Due to the wealth of expertise within the academic
community, firms close to this community stand to gain from enhanced knowledge
transfer in this field.   Thus study of interactions between academics, suppliers of
software solutions and pharmaceutical firms is important in understanding how firms are
building competencies in bioinformatics.
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It has been stated previously a shortage of trained bioinformatics professionals exists
90,
and interview data has confirmed firms still see recruitment of staff as one of the most
major barriers to entry for bioinformatics. Researchers from the Biological and
Biotechnological Science Research Council, were even able to estimate there is demand
for 50% more employees in large firms operating bioinformatics departments
91.
The exact role of bioinformaticians in these departments may vary in large firms seeking
integration, but generally they take part in four activities: developing new tools, acting as
internal consultants to help bench scientists using tools, assessing external offerings, and
working on the infrastructure to link tools.  In firms following a piecemeal approach to
using tools their activities may be more limited in terms of development and focus on
using the software tools for research and assisting other to do so, as well as advising on
the purchase of new tools.
Whatever the exact requirements they face, the number of bioinformaticians available to
firms at present places a strain on late entrants to replicate the developments of
established teams of early entrants.   Furthermore, firms who do not build in-house
competencies may lose the ability to derive maximum benefit from externally produced
technology, as noted by Bains
92 and Granstrand,  Patel,  Pavitt
93 and as a result may miss
new technological opportunities as noted by Teece and Pisano
94.
It may be necessary to carry out more research into differences between firms in new
technological capabilities that relate to pharmaceutical R&D process change to discover
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the extent to which new competitive advantages are being developed, and how that may
affect the structure of the industry as a whole.  Furthermore it must be highlighted the
benefits of bioinformatics are yet to be fully realised, as fully integrated systems do not
currently exist, and their effectiveness in producing licensed drugs are unproven as no
drugs have been developed solely as a result of them.  Others suggest the full impact of
bioinformatics will be apparent only after the establishment of pharmacogenomics
95&96.
This could prove to be an entirely new dimension in healthcare, that is presently
impractical but might be possible in the medium term to long term.
It is must also be stated other mechanisms of drug discovery based around imitation will
still support firms not seeking to develop entirely novel treatments.  Complex
bioinformatics may be hard to imitate, but it does not provide a means of preventing
competitors imitating final products.
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Glossary of Terms
Animal Model
Development of a disease condition in animal subjects, then used to prove the
effectiveness of therapeutic agents prior to testing on humans.
Bioinformatics / Computational biology
The storage, retrieval and analysis of data for scientific research aimed at providing
answers to biological questions
Candidate (drug candidate)
Term used to describe a promising new chemical entity suitable to be passed into clinical
trials.
Combinatorial chemistry
The systemic and repetitive covalent connection of a set of different building block of
varying structure to each other yielding a large array of diverse molecular entities.  This
technique may used to generate many new chemical entities to rapidly screen against
targets.
CRO (Contract Research Organisation)
A firm undertaking research, typically screening or validation, instead of (or to fund)
their own research activities
DBF (Dedicated Biotechnology Firm)
A firm producing products or services based on biotechnological techniques rather than
those of traditional synthetic chemistry.
DNA sequencing
A process, generally automated, where by DNA can be read to produce a series of bases
equivalent to a binary code.  The coding bases are read in units of three bases called
“codons”.  Each DNA Codon represents one amino acid which in turn are the basic65
building blocks of proteins.  Therefore from DNA sequencing it is possible to determine
the type of protein encoded, and often other characteristics too.
Drug Discovery Firm
Firms dedicated to research generating targets or leads, with the intention of selling
research results to other organisations, rather than attempting to produce licensed drugs.
FDA (Food & Drug Administration)
The American government organisation responsible for the licensing of drugs.  Because
America offers the largest single market for most commercial drugs, and has one of the
harshest regulating authorities, firms generally aim for FDA approval standards.
Genomics
The study of genes and genomes (the sum of an organism’s genes) through data collected
by DNA sequencing.  Genomics allows not only the number of copies and their positions
in the genome to be known, but increasingly function and mutation (and thus pre-
disposition to disease) can be identified.
Lead compound
Term used to describe a promising new chemical entity in the early stages of the
discovery process. Leads successfully completing screening and toxicology stages may
then become drug candidates.
Pharmacogenomics
The use of genetic information from the patient to determine which of a group of
treatments will have the most beneficial effect on their disease.  The cause of disease may
stem from one of several genetic pre-dispositions according to the specific illness, thus
finding out which is the source of a patient’s illness may in the future lead to the
prescribing of more effective drugs to a patient population sub-divided categories
according to genetic profile.
Proteomics
The study of proteins, their structure and function.  Increasingly Protein structures are
available, and may be allowing proteins to be classified by function and relationships to
other known proteins.66
Screening (High Through Put and Combinatorial)
A process of testing new chemical entities against large numbers of targets to see if they
show any desired result.  Increasingly screening is becoming automated, allowing the
routine processing of large libraries of compounds.
SME (Small to Medium sized Enterprise)
A firm of not more than 500 employees.
Software tool
Software capable of performing a multiple or single tasks (eg searching for a DNA
sequence, or recognising patterns in data).  Software suites or systems may be made up of
numerous software tools that may interact.
Target
The point a therapeutic agent intervenes at a molecular level to interrupt the disease
process.  Targets may be genes, proteins, or other molecules.
Validation
Confirmation experimentally that a target or lead is responsible for an observed effect in
the metabolic pathway of interest.67
Appendix 1: Interviewees
Representing Pharmaceutical Firms
Large Firm A, Interviewee A1, Unit head, Advanced Technologies and Informatics
Large Firm B, Interviewee B1, Director of Bioinformatics UK
Interviewee B2, Alliance and Technology Group
Large Firm C, Interviewee C1, Head of Genetic Technologies
Medium Firm D, Interviewee D1, Molecular Biologist
    Interviewee D2, Molecular Modeller
SME Firm E, Interviewee E1, Principle Scientist
Representing Universities:
Thornton Janet, Prof. Biomolecular Structure and Modelling Group
Dept. Biochemistry and Molecular biology, University College London
Woolfson, Dek, Biochemistry, University of Sussex
Representing Others:
Harding, Debbie (Researcher) Biological and Biotechnological Science Research Council
Maclean, Marlie (Researcher) Biological and Biotechnological Science Research Council
Informatics Consultants firm F, Interviewee F1 (Bioinformatics consultant)68
Appendix 2: Interview Questionnaire to Pharmaceutical Firms
Section 1: General Background
Company name:
Person Interviewed and Position held:
 Section 2: What Strategies are firms using to access the technologies and tools of
bioinformatics?
a)  How Long has bioinformatics been used in your firm and why did they move into the
area?
b)  Before Bioinformatics what did the drug discovery and development pathway in your
firm look like?  Please indicate limiting steps, sourcing and barriers (eg. cost high
failure rate).
c)  How is the pathway in your firm set to look (short to medium term)?  Again please
indicate systems you use, sourcing, limiting steps, and barriers to progress and
reasons why.
d)  Is integration of software sytems occurring yet (as in banking sector), or is technology
still in separate "boxes"?
e)   Are you developing internal capacities or out sourcing? Is software developed in
house or bought off the shelf (is it developed by IT consultants, Public sector
researchers, or internal programmers?)
f)   Is there a complex relationship with suppliers of hardware and software involving
after sales care and feed back for R&D, alliances and licences?
g)  Does innovation in this field make hardware obsolete quickly and is this a  problem
for buying equipment for your programs.69
Section 3: How are these technologies being integrated into development
process in studied firms?
a)  How far off is the "holy grail" of structural models gained purely from sequence data?
b)  Who are the end users of bioinformatics and what skill training do they have?
c)  Will the end user change in profile (e.g. specialist today, but bench scientists in
future)?
d)  Will different systems in separate organisations be able to “talk” to each other?
e)  What do you see as the major barriers to integration of bioinformatics systems in your
firm?  What reasons make them barriers? Is there in innovation paradox (biologists
don’t know what systems can do therefore can’t ask engineers to make it)
Section 4: How will bioinformatics change the focus of activities in those
firms?
a)  Will the limiting step of the drug discovery process change from being target
discovery to a later stage?
b) Will they out-source more or downsize R&D departments if the work is less
intensive in terms of man-hours?
c) Will it become easier for small less integrated firms to develop targets on their own?
Could this affect the structure of the industry?
d) What do you see as being the major impact of bioinformatics in the medium
       to long term?70
Appendix 3:  Interview Questionnaire to Non-Firms
Section 1: General Background
Organisation:
Person Interviewed:
Background: (how long has bioinformatics been used in your dept, and what skill training
do staff have.)
Section 2: What Strategies are firms using to access the technologies and
tools of bioinformatics?
h)  Are pharmaceutical firms all developing internal informatics capabilities or out-
sourcing portions to external sources?
i)   Is the software that firms are developing developed in house or bought off the shelf
(is it developed by IT consultants, Public sector researchers, or internal
programmers?)
j)  Who is designing the hardware and software systems used (bioinformatics specialists
or old familiar IT firms, new IT firms or a mixture)?
k)   Is there a complex relationship with suppliers of hardware and software involving
after sales care and feed back for R&D, alliances and licences?
l)  Does innovation in this field make hardware obsolete quickly and is this a  problem
for those buying equipment to run programs in house?
m) When academics claim bioinformatics is easy and relatively cheap to access, why are
large pharma spending so much - do large firms have to replicate external
developments? Why?71
Section 3: How are these technologies being integrated into development
process in studied firms?
f)  Are software systems being integrated (as in banking sector), or is technology still in
separate "boxes"?
g)  How far off is the "holy grail" of structural models gained purely from sequence data?
h)  Will there be a “windows” type standard, and who will make it?
d)  Who are the end users and what skill training do they have?
e)  Will the end user change in profile (e.g. specialist today, but bench scientists in
future)?
f)  Will different systems in separate organisations be able to “talk” to each other?
g)  What do you see as the major barriers to integration of bioinformatics systems in
firms? Is there still a design paradox?
h)  Is there any variation in how the firms are using Bioinformatics?72
Section 4: How will bioinformatics change the focus of activities in
pharmaceutical firms?
a)  Will the limiting step of the drug discovery process change from being target
discovery to a later stage?
b)  Will they out-source more or downsize R&D departments if the work is less
intensive in terms of man-hours?
c)  Will it become easier for small less integrated firms to develop targets on their
own?
d)  Will there come a time when the industry does it’s own in house development
and does not need software firms?
e) What do you see as being the major impact of bioinformatics in the medium
       to long term?
f) Does it seem likely some of these will fail to fulfil future needs, thus causing
competitive differences between firms in the future.